BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it
will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and
in combination with Genentech’s TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer’s (SITC) 31st
Annual Meeting & Associated Programs taking place November 9 – 13 in National Harbor, Maryland.
Following are the details of Corvus' two poster presentations:
- Phase 1/1b multicenter trial of CPI-444, an adenosine A2a receptor (A2aR) antagonist as a single agent and in
combination with atezolizumab (atezo) in patients with advanced solid tumors (Poster #149)
Authors: John Powderly II1 (presenter), Joshua Brody2, John Nemunaitis3,
Leisha Emens4, Jason J. Luke5, Amita Patnaik6, Ian McCaffery7, Richard
Miller7, Ginna Laport7
Affiliations: 1Carolina BioOncology Institute, Huntersville, NC; 2Mount Sinai
School of Medicine, New York, NY; 3Mary Crowley Cancer Research Center, Gradalis, Inc., Medical City Dallas Hospital,
Baylor University Medical Center, Dallas, TX; 4Johns Hopkins School of Medicine, Baltimore, MD; 5University
of Chicago School of Medicine; 6 South Texas Accelerated Research Therapeutics, San Antonio, TX, 7Corvus
Pharmaceuticals, Burlingame, CA
Session Date and Time: Friday, November 11, 12:15 – 1:30 p.m. and 6:15 – 7:30 p.m. ET
Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB
- CPI-444: a potent and selective inhibitor of adenosine 2A receptor (A2AR) induces anti-tumor responses alone and in
combination with anti-PD-L1 (Poster #218)
Authors: Andrew Hotson1 (presenter), Stephen Willingham1, Po Y. Ho1, Carmen
Choy1, Ginna Laport1, Ian McCaffery1, Richard Miller1
Affiliations: 1Corvus Pharmaceuticals, Burlingame, CA
Session Date and Time: Saturday, November 12, 11:45 a.m. – 1:00 p.m. and 6:45 – 8:00 p.m. ET
Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small
molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial
immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to
disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is
a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and
in combination with Genentech’s TECENTRIQ (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with
Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For
more information, visit: www.corvuspharma.com.
Investor Contact: Jason Coloma, Ph.D. SVP and Chief Business Officer 650-900-4511 JColoma@corvuspharma.com Media Contact: Julie Normart, W2O Group 415-946-1087 jnormart@w2ogroup.com